Navigation Links
Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
Date:6/22/2011

CHAPEL HILL, N.C., June 22, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the 2011 Wells Fargo Healthcare Conference at 1 p.m. EDT, June 23, 2011, in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and other infections and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
2. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
3. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
4. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
5. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
7. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... BUENA, N.J. , May 27, 2015  IGI ... Jersey -based specialty generic pharmaceutical company, today updated ... Second Quarter and Full Year 2015 Updated ... three months ended June 30, 2015 are still expected ... sequential improvement quarter over quarter in total revenue for ...
(Date:5/27/2015)... ZIONA, Israel , May 27, 2015 /PRNewswire/ ... Capital has led an investment round of $10 million in ... participation by the company,s chairman and CEO Mr. Ehud ... company,s clinical development plans; the funding is sufficient to advance ... once every four weeks injection, currently at Phase II, up ...
(Date:5/27/2015)... , 27. Mai 2015 Experten ... GERD) diskutierten im Rahmen einer Spezialpräsentation auf ... Erfahrungen mit der Stretta-Therapie für ... Patientengruppen. Infografik - ... , MD, von der Case Western Reserve ...
Breaking Medicine Technology:IGI Laboratories Updates Business Outlook 2IGI Laboratories Updates Business Outlook 3Mapi Pharma Closes $10 Million Investment Led by Shavit Capital 2DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 2DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 3DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen 4
... Sigma-Aldrich (Nasdaq: SIAL ) announced today that it ... leader in bench top flow chemistry instruments, the terms ... of approximately 400 CatCart® catalyst products for flow chemistry ... and CatCart catalyst cartridges provide organic chemists in academic ...
... Accumetrics, Inc., developer and marketer of the VerifyNow® ... measuring an individual,s response to multiple antiplatelet agents, announced ... that will raise $16.5 million in new capital. ... into 2011, came from the company,s existing investors, including ...
Cached Medicine Technology:Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 2Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 3Accumetrics Announces $16.5M in New Capital Financing 2Accumetrics Announces $16.5M in New Capital Financing 3
(Date:5/27/2015)... (PRWEB) May 27, 2015 SAN ... in Gulfport Mississippi, is the first healthcare provider ... approach to chronic care management (CCM). In partnership ... Memorial is introducing RevUp, a new program that ... requirements and increase monthly reimbursements. This new, user-friendly ...
(Date:5/27/2015)... HOUSTON, Tx (PRWEB) May 27, 2015 ... combined germline pharmacogenomic and somatic genomic analysis in personalized ... was published by the American Society of Clinical Oncology ... – June 2 in Chicago. , The molecular and ... The Cancer Genome Atlas (TCGA) database. The study reports ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 On June ... advertising agency, will partner with LifeSource to host Donate ... will take place in a LifeSource donor coach outside ... to 4:00 p.m. , Demand for whole blood units ... Illinois, during the summer months. LifeSource requires approximately 1,000 ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 ... the current state of the Omega-3 industry. The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ... Gc Rieber Oils, Camanchaca Fishing Company, Seadragon Marine ...
(Date:5/27/2015)... May 27, 2015 SonarMD, ... SonarMD Platform, a first-of-its kind, cloud-based algorithmic ... patients with chronic gastrointestinal disease. , Developed ... the application allows physicians to monitor their ... ongoing use of electronic health assessment surveys. ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... A new vaccine called the TAT vaccine has been developed ... to date. And more importantly it has had a 71% ... ready for human testing and this may be the brightest ... Head of the Department of Virology at Italy’s National Health ...
... Allergy and asthma patients can now breathe easy. Literally. A ... be effective in improving the quality of life and has ... findings of this study are reported in the latest issue ... M. Walker, PhD, of the Imperial College School of Medicine ...
... been used to test the importance of sleep for ... of side effects, such as fatigue and reduced alertness. ... circumventing these complications by allowing recovery sleep by Harvard ... the first day showed no improvement in task performance ...
... so aggressive and almost impossible to handle at times? Then read ... the children of today are growing up. Even the West is ... India. With the TV boom and the IT revolution, the kids ... parents complain that their kids are actually going over the edge, ...
... at the just concluded Indian science congress in New Delhi ... combat anemia with iron fortification of crops. Almost 50% of ... anemic in India. While iron supplementation is expensive, fortification of ... anemia in people is fairly cheaper, scientists say. ,This ...
... to increased risk of heart problems to their children ... several aspects of cardiovascular risks in adult life, but ... mothers starved during the first 13 weeks of pregnancy ... Starvation during mid or late pregnancy don’t have a ...
Cached Medicine News:
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
The Embla 384 cell washer is a top-loading, robotic-compatible microplate washer for high throughput screening. It is designed specifically for cell-based assays, which require a gentler wash, but ca...
Elisa Plate Reader...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Medicine Products: